Invited Guest Speaker Events

Dr. Spencer Proctor

  • September 2005: Canadian Lipoprotein Conference.  Pfizer Young Investigator Award 2004 (Quebec) Audience: 100 total; trainees and Academics
  • October 2005: Royal Veterinary College, University London.  United Kingdom. Audience: 50 total; trainees and Academics
  • March 2006: Atherosclerosis in Diabetes: an accelerated form or a new genesis? Muttart Diabetes Research and Training Centre, University of Alberta.  Audience: 50; trainees and Academics
  • March 2006: Interaction of Lipoproteins within the Vessel Wall: Impact of intestinal   chylomicron metabolism to Atherogenesis. Department of Laboratory Medicine and Pathobiology Invited Seminar Series, University of Toronto Sponsored by Merck/Schering.  Audience: 70; trainees and Academics
  • March 2006: Atherosclerosis as a postprandial disease: Clinical impact of chylomicron-remnant atherogenicity. Molecular Cell Biology of Lipids Seminar Series, University of Alberta, Edmonton, Canada. Sponsored by Merck/Schering.  Audience: 50 total; trainees and Academics
  • July 2006: Beyond Cholesterol and Atherogenesis. Heart Research Institute, Sydney Australia.  Audience: 30; trainees and Academics
  • August 2006: Postprandial Dyslipidemia in a rat model of the metabolic syndrome. Medical Research Foundation, University Department of Medicine, Royal Perth Hospital, Perth Western Australia.  Audience: 30; trainees and Academics
  • December 2006: Chylomicron and apoB48 metabolism in the JCR:LA corpulent rat, a model for the metabolic syndrome. Invited Talk for A Biochemical Society Focused Meeting. Diet and cardiovascular health: Chylomicron remnants and their emerging roles in vascular dysfunction in atherogenesis.  Audience: 40; trainees and Academics 
  • December 2006: Postprandial Lipoprotein Metabolism and implications for Atherogenesis and Insulin Resistance. Merck/Schering Heath Science Associate National Staff Meeting. Sponsored by Merck/Schering.  Audience: 10 total; Industry representatives
  • May 2007: Profiling New Research Natural Trans Fats and the Metabolic Syndrome. Nutri-Cast Beef Information Centre and Canadian Diabetes Association nutricast.ca Audience:  100’s; trainees and Academics
  • May 2007: Overview of Achievements for Human Health Module. CLA Network Summit Audience:  80; trainees and Academics
  • May 2007: Post-prandial lipoprotein metabolism in obesity and CVD risk. Western Obesity Summit. Audience:  100; trainees and Academics
  • Sept 2007: National Atherosclerosis Forum. Pfizer Canada Inc. Montreal. Invited national conference for Lipids and Atherosclerosis. Audience: 80; trainees and Academics
  • March 2008: Chair, International Symposium on Chylomicron in Disease, Lake Louise, Canada. Audience: 80 trainees and Academics
  • September 2008: National Atherosclerosis Forum. Pfizer Canada Inc. Toronto, Canada (Invited national conference for Lipids and Atherosclerosis.  Audience: 30; Academics and Industry
  • October 2008: Co-Chair and Invited speaker, Symposium on Chylomicrons, CSATVB Session of Canadian Cardiovascular Congress, Toronto, Canada. Audience: 800; trainees and Academics
  • November 2008: Invited Speaker, World Dairy Congress, Dairy Nutrition Sessions IDF, Mexico City. Audience: 100; trainees and Academics.
  • April 2009: Invited Speaker, Faculty of Life Science, University of Manchester Seminar, Manchester, England. Audience: 30; trainees and Academics
  • June 2009: Invited Speaker, DMI/National Dairy Council, Institute of Food Technologists (IFT) Annual Meeting and Food Expo, Anaheim, USA. Audience:  100; trainees and Academics
  • July 2009: Invited Speaker, School of Medicine and Pharmacology, University of Western Australia.  Audience: 30; trainees and Academics
  • August 2009: Invited Speaker, University of Cincinnati, Children's Hospital. Cincinnati, USA. Audience: 30 total; trainees and Academics
  • September 2009: Invited Speaker.  Saturated fatty acids and trans fatty acids in diary fat.  World Diary Summit, Berlin, Germany.  Audience: 200; trainees and Academics
  • September 2009: Invited Speaker, 11th Annual National Atherosclerosis Forum, Montreal, Canada. Audience: 50; Academics
  • October 2009: Invited Speaker, CSATVB Workshop, Edmonton, Canada. Audience: 50; trainees and Academics
  • November 2009: Invited Speaker, University of Guelph Seminar, Guelph, Canada. Audience: 30; trainees and Academics
  • June 2010: International Symposium on Chylomicron in Disease Conference, Rotterdam, the Netherlands. Audience: 40; trainees and Academics
  • September 2010: Invited Speaker, Impact of ezetimibe on post prandial lipid metabolism and vascular disease in the insulin resistant JCR:LA-cp rat.  12th Annual National Atherosclerosis Forum, Montreal, Canada. Audience: 30; Academics
  • September 2010: Invited Speaker, Coronary Syndromes and Atherosclerosis: coronary artery disease, lipids and signaling in atherosclerosis and heart disease, vascular biology, and cardiac energy metabolism.  Mazankowski Alberta Heart Institute, Maz Connects: Meet the Researchers Luncheons.  Edmonton, Canada. Audience: 50; trainees and Academics
  • October 2010: Chairing CSATVB Session II, Cardiovascular Congress, Montreal, Canada. Audience: 80; trainees and Academics
  • November 2010: CVRC Seminar, Edmonton, Canada. Rat Model of intestinal chylomicron over-production and Ezetimibe treatment: Impact on the retention of cholesterol in arterial vessels. Audience: 50; trainees and Academics
  • March 2011: ISORAM (International School on Obesity Research and Management), Lake Louise, Canada.  Understanding how non-fasting lipids increase cardiovascular risk in adult and pediatric obesity. Audience:  50; trainees and academics
  • May 2011: Lipid Metabolism Symposium, Ottawa Hospital, Metabolism Research Initiative (OMRI), Ottawa, Canada.  Clinical implications of remnant dyslipidemia, new insights into raised apolipoprotein-B48 in Type-1 diabetes Preliminary data of apolipoprotein-B48 in Obese Children? Audience: 50; trainees and academics
  • June 2011: Alberta Livestock and Meat Agency (ALMA) Future Fare event.  Edmonton, Canada.  Trans vaccenic acid and the link to healthy humans.  Audience: 200; trainees, academics, industry and government
  • June 2011: Affiliate Meeting Presentation for Alberta Milk.  Edmonton, Canada.  CLA, vaccenic acid and the CLA Network. Audience: 30; Industry and dietitians
  • October 2011: CSATVB Trainee Workshop, Vancouver, Canada. Targeting basic science for Translation: Understanding your ideas well enough to capture (financial) opportunities. Audience: 50; trainees industry and academics
  • October 2011: Canadian Cardiovascular Congress (CCC) 2011 chaired session “Obesity, Lipid Metabolism and Lipotoxicity”.  Vancouver, Canada. Audience:  50; trainees and academics
  • November 2011: Agriculture and Agri-Food Canada, Food Regulatory Issues Division.  Trans Fatty Acids Web Conference.  Health aspects of trans fatty acids (animal studies and mechanisms).  Audience:  20; Government and industry
  • November 2011: University of Manchester.  Understanding the vascular complication of the JCR:LA-cp rat for use in stroke.  Manchester, UK.  Audience 20; Academics and trainees.
  • March 2012: International Society of Chylomicrons in Disease.   XVI International Symposium on Atherosclerosis Satellite Meeting.   Keynote Speaker on Postprandial Lipaemia, Remnant Lipoproteins and Atherosclerosis.  Sydney, Australia.  Audience 30;  Academics and trainees.
  • September 2012: Jingzhou 2012 International Conference.  Ruminant trans-11 vaccenic acid decreases fasting and post-prandial hypertriglyceridemia by reducing both hepatic and intestinal TG secretion and associated genes in a rat model of the metabolic syndrome.  Jingzhou, Hubei, China.  Audience 200:  Academics and trainees.
  • October 2012: ILSI China Transfat Symposium. “General Introduction on Natural and industrial trans fats”.  Beijing, China. Audience 200:  MOH officers, CDC experts, University experts, and Industries.  Audience 200:  MOH officers, CDC experts, University experts, and Industries.
  • November 2012: 46th Annual Nutrition Society of New Zealand and Worldwide Universities Network (WUN) workshop/forum.  Auckland, New Zealand.  Audience 120; Academics and trainees.
  • January 2013: Dairy Australia & Food Standards Australia New Zealand (FSANZ) & Australian Food and Grocery Council (AFGC).  Canberra, Australia.  Audience 20; Government, industry and academics.
  • May 2013: HDL Workshop as part of the ATVB –American Heart Assoc Sessions. Audience 40
  • February 2014: Alberta Diabetes Institute, Research Seminar, University of Alberta, Audience 80.
  • March 2014: Symposium on Chylomicrons in Disease (ISCD) Tokyo, Japan Audience 100
  • April 2014: Vancouver Heart and Lung Institute, Research Seminar Series Audience 60
  • October 2014: Simon-Pierre Noel Lectureship, Canadian Lipoprotein Conference 2014, Audience 100
  • March 2015: Keynote speaker.   HDL particles number vs functionality; what really matters? Mazankowski Alberta Heart Institute-Journal Club.  Audience 100; Academics and trainees.
  • May 2015: Award Seminar.  Contributions of dietary lipids to pathways of CVD: Lessons learned from the Intestine, Young Investigator Award for Outstanding Research, Canadian Nutrition Society Annual meeting, Winnipeg, Canada.  Audience 100; Academics and trainees.
  • June 2015: Keynote Speaker.  Contributions of intestinal APOB Lipoproteins to Plaque Cholesterol:  Evidence from Bench to Bedside During Childhood Obesity. 1st International Convention Immunopharmacology-Vaccipharma 2015.  Varadero Beach, Cuba.  Audience 200; Academics and trainees.
  • March 2016: Role of Remnant Cholesterol in Atherosclerosis and Sub-clinical CVD risk.  Seminar and Round Table Discussion.  Department of Pharmacology.  New York Medical College, New York. Audience 80; Academics and trainees.
  • May 2016: Hypolipidemic and cardioprotective benefits of a novel Fireberry Hawthorn fruit extract in the JCR:LA-cp rodent model of dyslipidemia and cardiac dysfunction. CHIRI Seminar, Faculty of Health Sciences, University of Curtin, Western Australia, Australia.  Audience 75; Academics and trainees.
  • May 2016: Heart and Stroke Awareness Week.  University of Alberta Li Ka Shing Center Labortories, Edmonton, Canada.  Audience 75; Academics and trainees.
  • Sept 2016: Role of Remnant Cholesterol in Atherosclerosis and Sub-Clinical CVD risk.  Cardiology Grand Rounds, Mazankowski Heart Institute, University of Alberta Hospital.  Edmonton, Canada.  Audience 75; Academics and trainees.
  • May 2017: The use of pre-clinical models to investigate the proof of principal to inhibit the interaction of lipids with arterial proteoglycan during atherosclerosis. Centre for Molecular and Immunology, University of Havana, Cuba.  Audience 100; Academics and trainees.
  • May 2017: Therapeutic potential of vaccenic acid in intestinal inflammatory diseases.  School of Medicine and Pharmacology, University of Western Australia, Perth.  Audience 40; Academics and trainees.
  • June 2017:  Remnant Cholesterol in Atherogenesis: Vascular interactions, novel biomarkers and emerging therapeutics. CVRC Seminar Series, University of Alberta, Edmonton, Canada.   Audience 50; Academics and trainees.
  • July 2017: Lymphatics as a functional conduit in whole body lipid homeostasis: Role for lymphatic HDL & apoAI. FASEB Summer Research Conference, Snowmass, Aspen CO, United States. Audience 50; Academics and trainees.
  • September 2017: Role of Remnant Cholesterol in Atherosclerosis and Sub-clinical CVD risk.  Center for Diabetes and Vascular Medicine, Franciscus Gasthuis Rotterdam.  The Netherlands.  Audience 80; Clinicians and trainees.
  • January 2018: Remnant cholesterol and non-fasting lipids contribute to CVD progression: Are overweight youth at risk? (Seminar Series). Children’s Hospital Research Institute, Department of Paediatrics, Division of Endocrinology.  University of British Columbia, Vancouver. BC. Audience 30; Clinicians, Academics and trainees.
  • February 2018: (Trans) Fatty Acids and Human Health (can we enrich Beef to be more healthful? Beef Quality Workshop. Ruminant Trans Fatty Acids for Human Health. Lacombe, Alberta. Audience 30; Stakeholders, Farmers, Academics and trainees.
  • June 2018: Impact of Diabetes on Remnant (and apoAI) Metabolism: Role for Niacin. Invited Speaker, International Symposia for Atherosclerosis, Toronto, June 2018.
  • March 10-14, 2019: Invited talk and Research Workshop. Non fasting Lipids, fat intolerance and early predictors of CVD risk. Centre for Immuno-Metabolism, (CIM), Varadero, Cuba. Audience 30; Stakeholders, Academics and trainees.
  • May 2019: ApoB-Remnant Dyslipidemia and High-Fat Meal Intolerance in Overweight-Obese Children.  Lifestyle, Metabolism & CVD Risk Satellite to the European Atherosclerosis Society Annual Meeting, Maastricht, Netherlands May 25, 2019. Audience 500; Academics and trainees.
  • November 2019: The beginning & end of non‐fasting remnant cholesterol? Data from the ATP cohort & a novel antibody to target ASVD. Centre for Heart Lung Innovation Seminar Series St Paul’s Hospital, Vancouver. BC. Audience 30; Academics and trainees.
  • November 2019: Moderator at Women & Children’s Health Research Institute, Research Day 2019. Audience 50; Academics and trainees.
  • January 2020: The beginning & end of non‐fasting remnant cholesterol? Data from the ATP cohort & a novel antibody to target ASVD. Cardiovascular Research Centre Seminar Series, Edmonton, AB.  Audience 20; Academics and trainees.
  • February 2020: The evidence for treating TGs to further reduce CVD risk. Edmonton Citywide Journal Club ‘REDUCE-IT Trial, Edmonton, AB.  Audience 20; Academics, trainees, stakeholders, members of the public
  • May 2020: Moderator at the MCVD Sars-CoV-2 JC, Metabolic and Cardiovascular Diseases group (AFNS PI’s) Zoom Talk, Edmonton, AB. Audience 20; Academics and trainees,

Dr. Donna Vine

  • June 2011: Early Indicators of Atherogenic Dyslipidemia in Obese Adolescent Girls. University Department of Medicine, Royal   Perth Hospital Campus, University of Western Australia, Perth, Australia.
  • August 2011: Polycystic Ovary Syndrome: Exploring Mechanisms of Atherogenic Dyslipidemia in a Rodent Model.  School of Medicine and Pharmacology, University of Western Australia, Perth, Australia.
  • June 2012: Early development of atherogenic dyslipidemia in obese adolescents with PCOS. Androgen Excess and Polycystic Ovary Society. Houston, USA.
  • June 2012:. Atherogenic Dyslipidemia in Obese Adolescents and a Rodent Model of Polycystic Ovary Syndrome. Endocrinology, Houston, Texas, USA.
  • November 2012: Absorption and bioactivity of vaccenic acid in dyslipidemia and the metabolic syndrome. 46th Annual Nutrition Society of New Zealand.  Auckland, New Zealand.
  • January 2013: Apo-B remnant lipoproteins is associated with the metabolic syndrome in adolescents with and without PCOS in the RAINE Cohort.  School of Medicine and Pharmacology, Royal Perth Hospital.  Perth, Australia.
  • June 2014: Elevated Non-fasting and Fasting ApoB-lipoprotein Metabolism in Obese Adolescents with PCOS and Exacerbated Cardiovascular Disease Risk.  International Society of Endocrinology International Society of Endocrinology.  Chicago, USA.
  • October 2014: Free testosterone and impaired insulin sensitivity are positively correlated with plasma triglycerides and apob48-remnant lipoproteins in healthy-weight, obese controls, and obese adolescents with PCOS.  Androgen Excess and PCOS Society:  CME Lecture, Androgen Excess and PCOS Society.  Hawaii, Canada.
  • May 2015:  Dietary Lipids in Health, Diabetes and Cardiometabolic Risk:  Does the Future Lie in the Past?  Diabetes Educator Executive Committee (DES) - Northern Alberta.  Spring Thaw Meeting.  Edmonton, Canada.
  • May 2015: Polycystic Ovary Syndrome: An ‘old’ disease with a ‘new’ focus in adolescents at increased risk of Type-2 Diabetes and CVD.  Alberta Diabetes Institute Research Seminar Series.  Edmonton, Canada.
  • November 2015: Co-Chair and Honorable Speaker of Session 2 (Track: Effects of PCOS on Women’s Health) Dyslipidemia and Exacerbated Cardiovascular Disease Risk in PCOS: clinical assessment to exploration of potential mechanisms. PCOS 2015 Conference.  Seattle, USA.
  • July 2016: Dyslipidemia in Polycystic Ovary-Metabolic Syndrome: Clinical Setting & Understanding Mechanisms. School of Medicine and Pharmacology Seminar Series, University of Western Australia.
  • November 2016: Androgens Modulate Lipid Metabolism in a Rodent Model of Polycystic Ovary Syndrome.  14th AE-PCOS Annual Meeting, Victoria, Australia.
  • April 2017: Update on international lipid guidelines for diagnosis of risk.  Molecular Cell Biology of Lipids Scholar Group.
  • May 2017: The role of diet in Cognitive Decline, Dementia and Alzheimer’s Disease.  Education for Life, Centre for Health and Nutrition.  Edmonton, Canada.
  • October 2017: Androgens and Insulin modulate cardiometabolic risk factors via the androgen receptor. Androgen Excess and Polycystic Ovary Syndrome Society, United States. Androgen Excess and PCOS Society, San Antonio, United States.
  • December 2017: PCOS and Cardiometabolic risk: animal models to epidemiological assessment. Molecular and Cell Biology of Lipids Scholar Group, U of Alberta, Edmonton, Canada.
  • January 2018: Dyslipidemia in PCOS. Research Series: University of British Columbia, Dept Pediatrics, BC Children's Hospital Research Institute, Canada.
  • October 2018: ApoB48-Remnant Lipoproteins are Associated with Increased Cardiometabolic Risk in Adolescents with and without Polycystic Ovary Syndrome. Canadian Society Endocrinology and Metabolism/Canadian Diabetes Association, Annual Meeting, Halifax, Canada.
  • October 2018: PCOS Symposium: Type-2 Diabetes and Cardiovascular Disease in Polycystic Ovary Syndrome: the Reality and the Controversy?. Canadian Diabetes Association and Canadian Society of Endocrinology and Metabolism, Halifax, Canada.
  • October 2020: Androgen and Estrogen actions in cardiometabolic risk. Androgen Excess and PCOS meeting, San Francisco, US.
  • March 2021. Cardiovascular Disease in PCOS. U of A Hospital: Mazankowski Heart Research Institute: Prevention of CVD:Citywide Journal club.
  • September 2021. Androgen and Estrogen receptor function in Lipid and Endocrine Metabolism. World Congress on Diabetes and endocrinology, September 15-16,  2021.

Dr. Rene Jacobs

  • (2020). Old and new regulators of lipid metabolism and liver health. Cell Biology Seminar Series, Canada
    Main Audience: Researcher
  • (2019). Unravelling the role of Phosphatidylcholine synthesis in metabolic diseases. Department Seminar
    Series, Canada
  • (2019). Short stories about old and new regulators of liver health. 2019 Annual Biochemistry Retreat,
    Canada
  • (2018). Understanding the role of Phosphatidylcholine synthesis in Liver Disease. Conference of
    Gastroenterologist and Hepatologist of China, China
  • (2018). Phospholipid Metabolism and Liver Disease. Federation of American Societies for Experimental Biology (FASEB) Summer Research Conference on Folate, B12 and One-Carbon Metabolism, Canada
  • Canadian Nutrition Society Annual Meeting- Choline Status and Metabolic Disorders: A complicated Tale. Winnipeg, MB, June, 2015
  • Nutrition Institute Seminar- The role of phosphatidylcholine synthesis in the development of metabolic disorders. University of North Carolina, April 8, 2015
  • Department of Biochemistry Seminar - Understanding the role of one-carbon metabolism in the development of chronic diseases. University of Alberta, May, 2015
  • Department of Human Health and Nutritional Sciences Seminar- Role of one-carbon metabolism in the development of chronic diseases. Guelph, Canada, August 29, 2014
  • Department of Biochemistry and Molecular Biology Seminar- Understanding the role of one-carbon metabolism in the development of of chronic diseases. Dalhousie University, Halifax, Canada, April 2, 2014
  • 9th International Homocysteine and One-Carbon Metabolism Conference- Finding the Balance: PC Biosynthesis and NAFLD. Trinity College Dublin, Ireland, September 8th–12th, 7. 2013 Pharmacology Seminar- Understanding the Role of Phosphatidylcholine Biosynthesis in Metabolic Disorders. University of Virginia, October 11, 2012
  • Alberta Diabetes Institute Research Seminar- 1-carbon supplements for the treatment of metabolic disorders: risk versus rewards, October 1, 2012
  • Banff Egg Conference- Choline: The forgotten essential Nutrient. Banff, Alberta, March 31, 2012
  • Canadian Lipoprotein Conference- The metabolic consequences of altered choline metabolism. Halifax, November 3, 2011
  • Women and Child Research Institute Annual Research Day- Important role for dietary choline during lactation. Edmonton, November 26, 2010
  • Nutrition 440 Research Seminar- Choline: New roles for an old nutrient. Edmonton, Feb 2, 2010
  • Western Canada Nutrition Day- The role of choline in chronic diseases. Edmonton,
    November 28, 2009.
  • Agricultural, Food and Nutritional Sciences Seminar- Metabolic Syndrome X: Phosphatidylcholine marks the spot!” University of Alberta, November 2008
  • Alberta Institute of Human Nutrition Seminar- Impaired Phospholipid Methylation Protects Mice Against Diet-Induced Obesity and Insulin Resistance. University of Alberta, April 2008
  • Conference Presentation- Phosphatidylethanolamine N-methyltransferase Deficiency Protects Mice Against Diet-induced Obesity and Insulin Resistance. Deuel Conference on Lipids, Loews Coronado Bay Resort, California, March 2008
  • CIHR group on the Molecular and Cell Biology of Lipids Seminar- Hepatic CTP:phosphocholine Cytidylyltransferase-α: An Important Regulator of Plasma HDL and VLDL. University of Alberta, January 2008
  • Biochemistry Seminar- New Regulators of Hepatic Lipid Transport. 40 th Anniversary Scientific Colloquium, Memorial University of Newfoundland, October 2007
  • Biochemistry Seminar- PC Biosynthesis, Lipoprotein Metabolism, and Insulin Resistance-Studies in the Liver-specific CTα Knockout mouse. Memorial University of Newfoundland, August 2006
  • Conference Presentation- Phospholipid methylation and homocysteine secretion. FASEB summer conference, Vermont, June 2006

 

Dr. Caroline Richard

  • The Mediterranean diet to improve cardiometabolic risk factors: is weight loss required? Invited oral presentation at the Brazilian Society of Hypertension, August 6, 2021.
  • Understanding the obesity-related immune dysfunction: Nutrition and Immunity (NutrIMM) Study. Invited oral presentation at the CNS/Cardiometabolic Research Network Workshop. December 11, 2020. (Virtual meeting)
  • Choline an important nutrient for the immune system development. Invited talk at the Immunology Mini-Symposium. July 25, 2019, Li Ka Shing Center, University of Alberta. Edmonton.
  • Le babeurre: une importante source de choline pour le développement du système immunitaire/ Buttermilk: an important source of choline for the development of the  immune system. Invited speaker at Colloque STELA, 27-28 May 2019, Hotel Plaza Québec (Québec).       
  • L’importance des omega-3 et de la choline durant l’allaitement pour le système immunitaire de la mère et de l’enfant. Invited speaker at the Table-ronde provinciale des    nutritionnistes ouvrant en Médecine Fœto-Maternelle (MFM), 10 May 2019, Sherbrooke (Québec).
  • The Mediterranean Diet for the Management of Metabolic Syndrome in Men and Women: Is Weight Loss Required? Invited speaker at the Integrative Health Speaker’s Series, 12 March 2019, Edmonton Clinic Health Academy, Edmonton (Alberta).
  • The essentiality of docosahexaenoic acid (DHA) in infant diet for cognitive and immune development: current status of the evidence. Invited Lecture at the Canadian Nutrition Society. May 3-5, 2018, Halifax Convention Centre, Halifax (Nova Scotia).
  • Mitigating immune dysfunction related to chronic diseases through targeted dietary intervention. Invited Lecture at the Alberta Diabetes Institute Seminar Series. February 13, 2017, University of Alberta, Edmonton (AB).
  • Immune dysfunction in obesity-related chronic diseases: What is the role of nutrition? Invited Lecture at the Diabetes Spring Thaw (Diabetes Educators). May 6, 2017,   University of Alberta, Edmonton (AB).
  • The essentiality of docosahexaenoic acid in the postnatal maternal and infant diet for the development of the infant’s immune system early in life. Invited Lecture at the ImmuNet, October 27, 2016, University of Alberta, Edmonton (AB).